Dr Dhingra is currently heading KAPital Consulting, a company engaged in helping biotechnology, pharmaceutical and diagnostic companies realize the clinical and commercial promise of the advances in oncology.
David Hale, chairman of the board of Micromet, said: “We are honored to have Dr Dhingra join the board of directors. His significant success and proven track record in the development of oncology drugs will be a tremendous asset to Micromet as we advance our clinical stage product candidates to pivotal trials.”